Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4

[1]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[2]  R. Malinow,et al.  The prion protein as a receptor for amyloid-β , 2010, Nature.

[3]  P. Agostinho,et al.  Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. , 2010, Current pharmaceutical design.

[4]  D. Westaway,et al.  Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 Mutations , 2010, Cell.

[5]  S. Strittmatter,et al.  Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein , 2010, The Journal of Neuroscience.

[6]  Shaomin Li,et al.  How do Soluble Oligomers of Amyloid β-protein Impair Hippocampal Synaptic Plasticity? , 2010, Front. Cell. Neurosci..

[7]  M. Gobbi,et al.  Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein , 2010, Proceedings of the National Academy of Sciences.

[8]  S. Strittmatter,et al.  Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease. , 2009, Archives of neurology.

[9]  M. Kivipelto,et al.  Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later , 2009, Dementia and Geriatric Cognitive Disorders.

[10]  J. E. Evans,et al.  Long-Term Statin Therapy and CSF Cholesterol Levels: Implications for Alzheimer’s Disease , 2009, Dementia and Geriatric Cognitive Disorders.

[11]  G. Schellenberg,et al.  Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. , 2009, Archives of neurology.

[12]  G. Zamponi.  Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .

[13]  C. Xiong,et al.  Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challenges , 2009, Alzheimer's & Dementia.

[14]  Z. Khachaturian.  A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 , 2009, Alzheimer's & Dementia.

[15]  J. Poirier,et al.  Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Who may benefit from disease-modifying studies in Alzheimer's disease? , 2009, Alzheimer's & Dementia.

[16]  L. Mucke,et al.  Alzheimer's disease: A prion protein connection , 2009, Nature.

[17]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[18]  Larry D. Sparks.  Statins and cognitive function , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[19]  A. Arshad,et al.  STATINS, INCIDENT ALZHEIMER DISEASE, CHANGE IN COGNITIVE FUNCTION, AND NEUROPATHOLOGY , 2008, Neurology.

[20]  Sarah Aldred,et al.  Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. , 2008, Journal of Alzheimer's disease : JAD.

[21]  A Hofman,et al.  Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[22]  V. Ambros,et al.  The evolution of our thinking about microRNAs , 2008, Nature Medicine.

[23]  D. Sparks,et al.  Reduced risk of incident AD with elective statin use in a clinical trial cohort. , 2008, Current Alzheimer research.

[24]  J D Kalbfleisch,et al.  Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study , 2008, Neurology.

[25]  D. A. Bennett,et al.  Statins, incident Alzheimer disease, change in cognitive function, and neuropathology , 2008, Neurology.

[26]  D. Drachman.  Commentary on “A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium.” Prevention of dementia: Roadmap or maintenance manual? , 2008, Alzheimer's & Dementia.

[27]  F. Checler,et al.  Regulation of βAPP and PrPc Cleavage by α-Secretase: Mechanistic and Therapeutic Perspectives , 2008 .

[28]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[29]  D. Pollen,et al.  Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. , 2007, Archives of neurology.

[30]  E. B. Larson,et al.  Statin Therapy Is Associated with Reduced Neuropathologic Changes Statin Therapy Is Associated with Reduced Neuropathologic Changes of Alzheimer Disease , 2022 .

[31]  D. Selkoe,et al.  Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.

[32]  T. Miida,et al.  Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. , 2007, Pharmacology & therapeutics.

[33]  D L Sparks,et al.  Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol‐Lowering Treatment (ADCLT) trial , 2006, Acta neurologica Scandinavica. Supplementum.

[34]  F. Checler,et al.  The Disintegrin ADAM9 Indirectly Contributes to the Physiological Processing of Cellular Prion by Modulating ADAM10 Activity* , 2005, Journal of Biological Chemistry.

[35]  D. Pollen,et al.  Familial Alzheimer disease: Decreases in CSF Aβ42 levels precede cognitive decline , 2005, Neurology.

[36]  K. Blennow,et al.  Statin treatment and a disease-specific pattern of β-amyloid peptides in Alzheimer’s disease , 2005, Experimental Brain Research.

[37]  D. Sparks,et al.  Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. , 2005, Archives of general psychiatry.

[38]  Andrew Cordle,et al.  Neurobiology of Disease 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate-Amyloid-Induced Microglial Inflammatory Responses , 2005 .

[39]  A. Salam.  Expanding indications of statins; implications of the Heart Protection Study , 2003, Expert opinion on investigational drugs.

[40]  J. Dichgans,et al.  Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26‐week randomized, placebo‐controlled, double‐blind trial , 2002, Annals of neurology.

[41]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[42]  E. Kojro,et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[45]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[46]  P. Greengard,et al.  Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. Reiner,et al.  Regulation of Amyloid Precursor Protein Cleavage , 1999, Journal of neurochemistry.

[48]  H. Meziane,et al.  Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Mattson,et al.  Secreted β-Amyloid Precursor Protein Counteracts the Proapoptotic Action of Mutant Presenilin-1 by Activation of NF-κB and Stabilization of Calcium Homeostasis* , 1998, The Journal of Biological Chemistry.

[50]  P. Greengard,et al.  Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides , 1998, Nature Medicine.

[51]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[52]  S. Kohsaka,et al.  Involvement of amyloid precursor protein in functional synapse formation in cultured hippocampal neurons , 1998, Journal of neuroscience research.

[53]  M. Mattson,et al.  Activation of K+ channels and suppression of neuronal activity by secreted β-amyloid-precursor protein , 1996, Nature.

[54]  F. Checler.  Processing of the β‐Amyloid Precursor Protein and Its Regulation in Alzheimer's Disease , 1995 .

[55]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[56]  D. Small,et al.  A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[57]  S. Shimohama,et al.  Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. , 1991, Biochemical and biophysical research communications.

[58]  Gary Ruvkun,et al.  The Caenorhabditis elegans heterochronic gene lin-14 encodes a nuclear protein that forms a temporal developmental switch , 1989, Nature.

[59]  A. Aguzzi,et al.  Supplementary figure legends , 2010 .

[60]  P. Macfarlane,et al.  Pravastatin and cognitive function in the elderly. Results of the PROSPER study , 2009, Journal of Neurology.

[61]  P. Passmore,et al.  Statins for the prevention of dementia. , 2009, The Cochrane database of systematic reviews.

[62]  T. Golde.  Alzheimer's Research & Therapy , 2009 .

[63]  F. Checler,et al.  Regulation of betaAPP and PrPc cleavage by alpha-secretase: mechanistic and therapeutic perspectives. , 2008, Current Alzheimer research.

[64]  G. Schellenberg,et al.  Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. , 2006, Journal of Alzheimer's disease : JAD.

[65]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[66]  E. Kojro,et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[67]  P. Greengard,et al.  Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. , 1998, Nature medicine.

[68]  M. Mattson,et al.  Secreted beta-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-kappaB and stabilization of calcium homeostasis. , 1998, The Journal of biological chemistry.